FDA/CDC

FDA warns kratom vendors about unproven claims


 

The Food and Drug Administration has issued letters of warning to Chillin Mix Kratom and Mitra Distributing for making unproven medical claims about their kratom products – and therefore breaking federal law – according to a statement from FDA commissioner Scott Gottlieb, MD. These vendors both claimed that their kratom products could, among other things, “relieve” or “treat” opium/opioid withdrawal.

The Mitragyna Speciosa tree, from which the drug kratom is produced. ThorPorre/commons.wikimedia.org

The Mitragyna Speciosa tree, from which the drug kratom is produced.

“To date, there have been no adequate and well-controlled studies involving the use of kratom as a treatment for opioid use withdrawal or other diseases in humans,” noted Dr. Gottlieb.

As Dr. Gottlieb pointed out in his statement, not only can fraudulent health claims pose direct health risks, they can also, in the case of kratom, deter or delay people who’re suffering from opioid use disorder from seeking FDA-approved treatments that have been demonstrated to be safe and effective.

Dr. Scott Gottlieb


Kratom, also known more formally as Mitragyna speciosa, is a plant native to Thailand, Malaysia, Indonesia, and Papua New Guinea. Some compounds in the plant are believed to be opioids, some of which may have the potential for abuse. As Dr. Gottlieb pointed out in his statement, the substance is illegal or controlled in several countries and banned in some states and municipalities in the United States.

Find out more in Dr. Gottlieb’s full statement on the FDA website.

Recommended Reading

Assessing adverse events tied to outpatient opioid use in children
MDedge Neurology
Malpractice and pain management
MDedge Neurology
Nearly one-quarter of presurgery patients already using opioids
MDedge Neurology
Opioid use disorder is a chronic condition that needs ongoing therapy
MDedge Neurology
How to prescribe effectively for opioid use disorder
MDedge Neurology
Opioid use has not declined meaningfully
MDedge Neurology
FDA proposes broader outcomes for OUD treatment drug approvals
MDedge Neurology
More deliveries now include opioid use disorder
MDedge Neurology
Treating sleep disorders in chronic opioid users
MDedge Neurology
Opioids, other causes linked to shorter lifespans, rising midlife mortality
MDedge Neurology